To highlight advances and innovations in cancer therapy focusing on molecular pathways and signaling molecules.
Approach:
Overview of Molecular Pathways: Discusses the role of dysregulated cascades such as PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, and p53 networks in cancer progression and therapeutic resistance.
Integration of Immune and Metabolic Factors: Emphasizes the importance of understanding oncogenic signaling in relation to innate immunity, metabolism, and the tumor microenvironment (TME).
Multi-Omics and AI Analysis: Highlights advances in multi-omics profiling and AI-enabled analysis for identifying pathway-level biomarkers to guide cancer therapy.
Key Findings:
Molecular pathways and signaling molecules are critical targets for precision oncology.
The cGAS-STING pathway plays a dual role in tumor immunity and requires careful mechanistic understanding.
Lactate is identified as a significant signaling molecule influencing tumor behavior and immune evasion.
Interpretation:
The editorial underscores the need for a systems-level understanding of cancer signaling networks to improve therapeutic outcomes.
Limitations:
Inter- and intra-tumoral heterogeneity complicates treatment responses.
Challenges in integrating pathway activation with existing therapies like checkpoint blockade.
Conclusion:
The editorial emphasizes the importance of pathway-targeted agents and immunotherapies in overcoming cancer treatment resistance.
